galecto.com
Contact us
About company
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
DK
Unknown
Not verified company
Business transparency
- Did not verified company info
- Ask their customers for reviews
- Did not replied to negative reviews